Search
Changchun High-tech Announces Approval for Clinical Trial of Cabergoline Tablets by Subsidiary Gensci Pharmaceutical; Unique Product in Domestic Market
5 day ago /
Read about 0 minute
Author：小编
Changchun High-tech's subsidiary, Gensci Pharmaceutical, has recently secured approval from the National Medical Products Administration for the clinical trial application of its Cabergoline Tablets. Cabergoline Tablets, a dopamine receptor agonist, are designed for the treatment of hyperprolactinemia and pituitary prolactinomas. Notably, there are currently no comparable products available on the domestic market.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
